High-dose chemotherapy with carboplatin, etoposide, and melphalan for high-risk cancer
Author Information
Author(s): P Benedetti Panicil, L Pierelli, G Scambia, ML Foddai, MG Salerno, G Menichella, M Vittori, F Maneschi, U Caracussi, R Serafini, G Leone, S Mancuso
Primary Institution: Catholic University, Rome, Italy
Hypothesis
Does high-dose carboplatin, etoposide, and melphalan with peripheral blood progenitor cell support reduce toxicity and improve recovery in high-risk cancer patients?
Conclusion
The study found that high-dose chemotherapy with carboplatin, etoposide, and melphalan resulted in low non-haematological toxicity and fast haematopoietic recovery.
Supporting Evidence
- 32% of patients experienced a reversible grade III/IV increase in liver enzymes.
- Haematopoietic recovery was very fast in all patients.
- Patients treated with growth factors had significantly reduced hospital stays.
Takeaway
Doctors gave strong medicine to cancer patients to help them get better, and it worked well without making them too sick.
Methodology
Patients received high-dose chemotherapy followed by peripheral blood progenitor cell transplantation and were monitored for toxicity and recovery.
Limitations
The study was limited to a small sample size and specific cancer types.
Participant Demographics
Median age was 48 years, with patients having breast or ovarian cancer.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website